Poor
Needs Review
Patient Risk:
Moderate
Summary
Multiple user claims are not supported by the provided label excerpts (notably several 'most common side effects' and several severe adverse effect descriptions/resolution advice). Several safety-related claims are only partially aligned (some adverse reactions are supported, but others are not). Indication/dosing fundamentals are partially correct but omit key label limitations and context.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in the blood.
Label excerpt 1 includes reduction of TG levels in adult patients with severe hypertriglyceridemia (adjunct to diet) and provides clinical studies showing TG reduction (14.2).
Vascepa has been shown to be effective in reducing triglyceride levels.
Label excerpt 14.2 states VASCEPA 4 grams per day reduced median TG versus placebo in severe hypertriglyceridemia trial.
Vascepa can cause allergic reactions.
Label excerpt 5.2 advises informing patients with known hypersensitivity to fish/shellfish about potential allergic reactions and discontinuing and seeking medical attention if reactions occur.
Vascepa can cause anemia.
No provided label excerpt identifies anemia as a common or postmarketing adverse reaction.
Unsupported Statements
Vascepa is used to treat individuals with high triglyceride levels.
Label excerpt 1 specifies adjunct to maximally tolerated statin therapy for reducing risk of cardiovascular events in adults with elevated TG (≥150 mg/dL) with additional criteria, and adjunct to diet to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia. 'Treat high triglyceride levels' is too general and not limited to the label-specified populations/conditions.
The most common side effects of Vascepa include abdominal pain.
Provided label excerpt 6.1 lists common adverse reactions including musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation. 'Abdominal discomfort' is mentioned in postmarketing (6.2) but the claim states 'most common' and 'abdominal pain,' which is not supported by the provided excerpt.
The most common side effects of Vascepa include constipation.
Constipation is listed in 6.1 as a common adverse reaction (incidence ≥3%). However, the claim lists it among 'most common side effects' without providing the incidence context; still, this is largely supported by 'common adverse reactions' listing.
The most common side effects of Vascepa include diarrhea.
Diarrhea is mentioned in postmarketing experience (6.2) but is not listed as a common adverse reaction in 6.1.
The most common side effects of Vascepa include fatigue.
Fatigue is not listed in the provided adverse reaction excerpts (6.1 or 6.2).
The most common side effects of Vascepa include headache.
Headache is not listed in the provided adverse reaction excerpts (6.1 or 6.2).
The most common side effects of Vascepa include nausea.
Nausea is not listed in the provided adverse reaction excerpts (6.1 or 6.2).
The most common side effects of Vascepa include vomiting.
Vomiting is not listed in the provided adverse reaction excerpts (6.1 or 6.2).
The side effects of Vascepa are typically mild and temporary.
The provided label excerpts do not state that side effects are typically mild and temporary or describe time-to-resolution.
The side effects of Vascepa often resolve on their own within a few days or weeks of starting treatment.
The provided label excerpts do not state resolution timing for side effects.
Vascepa can cause anemia.
Anemia is not identified in the provided adverse reaction excerpts.
Vascepa can cause bleeding disorders.
The label excerpt 5.3 discusses bleeding risk/events, but it does not describe 'bleeding disorders' as an adverse reaction category. This is not directly supported as stated.
Vascepa can cause cardiac arrhythmias.
The label excerpt 5.1 specifically addresses atrial fibrillation/flutter risk requiring hospitalization; it does not broadly state 'cardiac arrhythmias.'
Vascepa can cause elevated liver enzymes.
The provided label excerpt 8.7 states that ALT/AST should be monitored in hepatic impairment, but it does not state that VASCEPA causes elevated liver enzymes.
Vascepa can cause gastrointestinal bleeding.
The label excerpt 5.3 discusses bleeding events generally, but does not specify gastrointestinal bleeding.
Vascepa can increase the risk of bleeding.
Label excerpt 5.3 supports increased risk of bleeding events; however the statement is broadly correct and aligns with label. (No contradiction; included here only if strictly evaluated as 'unsupported.' In this audit framework, this is supported—so it should not be in unsupported. )
Vascepa can cause kidney damage.
The provided label excerpts do not state kidney damage as an adverse reaction or risk.
Vascepa can cause pancreatitis.
Label excerpt 1 includes a limitation: effect on risk for pancreatitis has not been determined; it does not state that Vascepa can cause pancreatitis.
Vascepa can cause seizures.
Seizures are not listed in the provided adverse reaction excerpts.
Vascepa has not been studied in pregnant or breastfeeding women.
The provided label excerpt 8.1 states available data are insufficient to identify a drug-associated risk; 8.2 describes detection of omega-3 fatty acids in human milk and lack of data on effects of omega-3 ethyl esters on breastfed infant/milk production. This does not support the absolute statement that it has not been studied.
The use of Vascepa in pregnant or breastfeeding women is not recommended.
The provided label excerpt does not state 'not recommended' for pregnancy or lactation.
Vascepa may increase the risk of bleeding in individuals with a history of bleeding disorders.
The provided label excerpt 5.3 attributes increased bleeding incidence particularly with concomitant antithrombotic medications; it does not mention 'history of bleeding disorders.'
Vascepa may worsen kidney disease in individuals with pre-existing kidney damage.
No provided label excerpt supports worsening kidney disease in pre-existing kidney damage.
Vascepa may worsen liver disease in individuals with pre-existing liver damage.
The provided label excerpt 8.7 addresses monitoring ALT/AST in hepatic impairment but does not state VASCEPA may worsen liver disease.
Regular blood tests may be recommended to monitor liver and kidney function while taking Vascepa.
Label excerpt 8.7 supports monitoring ALT/AST periodically in hepatic impairment. It does not mention monitoring kidney function.
Regular blood tests may be recommended to monitor triglyceride levels while taking Vascepa.
The provided label excerpts advise assessing lipid levels prior to initiation (2.1). They do not state ongoing monitoring of triglyceride levels during therapy.
Severe side effects of Vascepa can include difficulty breathing.
Difficulty breathing is not listed in the provided warnings/adverse reaction excerpts.
Severe side effects of Vascepa can include chest pain.
Chest pain is not listed in the provided warnings/adverse reaction excerpts.
Severe side effects of Vascepa can include severe abdominal pain.
No provided excerpt lists 'severe abdominal pain' as a severe side effect.
Severe side effects of Vascepa can include vomiting blood.
No provided excerpt lists hematemesis or 'vomiting blood' as an adverse reaction.
Severe side effects of Vascepa can include black, tarry stools.
No provided excerpt lists melena or 'black, tarry stools' as an adverse reaction.
Contradictions
Low
AI Statement
If severe side effects occur while taking Vascepa, stopping the medication may be recommended until side effects resolve.
Label Reference
Label excerpt 5.2 advises patients with known hypersensitivity to fish/shellfish to discontinue VASCEPA and seek medical attention if reactions occur. However, the provided label excerpts do not give general instructions to stop VASCEPA for 'severe side effects' until resolution. The statement is therefore not supported rather than a direct contradiction.
Important Omissions
Indication limitations and required patient characteristics: label specifies adjunct to maximally tolerated statin therapy for cardiovascular risk reduction in adults with elevated TG (≥150 mg/dL) with established CVD or diabetes plus additional risk factors, and adjunct to diet for reducing TG in severe hypertriglyceridemia (≥500 mg/dL); it also includes a limitation that effect on pancreatitis risk has not been determined.
Importance:
Moderate
Administration/dosing regimen: label specifies total daily dose 4 g/day (four 0.5 g BID with food or two 1 g BID with food) and to swallow capsules whole; the evaluated statements did not include these details.
Importance:
Moderate
Specific boxed/label warning details: label highlights atrial fibrillation/flutter hospitalization risk and bleeding risk; several user claims about severe symptoms did not align with the label’s specific warnings.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about adverse reactions are not supported by the provided label excerpts (e.g., fatigue/headache/nausea/vomiting/diarrhea as 'most common', seizures, kidney damage, pancreatitis caused by VASCEPA). Additionally, absolute pregnancy/lactation statements and generalized monitoring advice are not supported as stated. This could mislead users about risk profile and appropriate expectations/monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Many safety/side-effect claims are not supported by the provided FDA label excerpts, and some pregnancy/lactation and monitoring statements are inaccurate or overstated.
Suggested Improvement
Restrict statements to those explicitly supported in the provided label excerpts: correct indication framing using the label’s TG thresholds and patient criteria; use label-supported common adverse reactions (musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation) and note that diarrhea/abdominal discomfort are postmarketing; avoid asserting unsupported severe symptoms; replace absolute pregnancy/lactation language with the label’s 'insufficient data' statements and specify hepatic impairment monitoring of ALT/AST rather than kidney monitoring.